In episode three of our fortnightly COVID-19 webinar series, portfolio manager Sunny Bangia and Jacob Mitchell discuss Chinese retail and the secular trends being accelerated by the coronavirus pandemic.
In this highlight, Sunny Bangia explains why he believes Alibaba is at the centre of the new retail phenomenon in China.
This webinar was recorded on 23 April, 2020. To view the full webinar, including comprehensive insights into where Antipodes sees compelling investment opportunities, click here.
You can register for upcoming webinars in the series here.
Episode 3 Part 2 – Transcript:
We kind of see Alibaba as the centre of this “new retail” phenomenon that’s occurring in China. Whilst they’re very dominant online, they’ve done incredibly important partnerships and built ancillary businesses that will facilitate this trend.
We know they’re a very big payments business in China, they have the leading payments wallet, called Alipay, with 960 million users. But also, they’re facilitating some of the trends that we’re seeing in FMCG (Fast Moving Consumer Goods) and grocery.
They have the leading grocery network being built out, called Hema Fresh, which is an online/offline grocery experience and they’ve made some key valuable partnerships with leading players in that space to be a platform to direct traffic and then do delivery – they also own the nation’s second largest delivery network called LMR.
So, when you think about the management team’s focus, they’re really taking the whole Chinese retail offline and online as the opportunity to grow.
Now in terms of regulatory, one thing we’ve highlighted in the take rates is firstly that there’s still a lot of late-term pricing power in the business model, which is fantastic. But we can also see that the regulatory framework… you know, you can’t accuse them of gauging. In a way they’re facilitating this e-commerce growth and there’s still a lot of monetisation left in the business model.
View the full webinar
This communication was prepared by Antipodes Partners Limited (ABN 29 602 042 035, AFSL 481 580) (Antipodes). Antipodes believes the information contained in this communication is based on reliable information, no warranty is given as to its accuracy and persons relying on this information do so at their own risk. This communication is for general information only and was prepared for multiple distribution and does not take account of the specific investment objectives of individual recipients and it may not be appropriate in all circumstances. Persons relying on this information should do so in light of their specific investment objectives and financial situations. Any person considering action on the basis of this communication must seek individual advice relevant to their particular circumstances and investment objectives. Subject to any liability which cannot be excluded under the relevant laws, Antipodes disclaim all liability to any person relying on the information contained on this website in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information.
Any opinions or forecasts reflect the judgment and assumptions of Antipodes on the basis of information at the date of publication and may later change without notice. Any projections are estimates only and may not be realised in the future. Information on this website is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained on the website is prohibited without obtaining prior written permission from Antipodes.
Pinnacle Fund Services Limited ABN 29 082 494 362 AFSL 238371 is the product issuer of funds managed by Antipodes. Any potential investor should consider the relevant Product Disclosure Statement available at www.antipodesonespartners.com when deciding whether to acquire, or continue to hold units in a fund. The issuer is not licensed to provide financial product advice. Please consult your financial adviser before making a decision. Past performance is not a reliable indicator of future performance.